Resources & Guides
Educational content about GLP-1 medications, pharmacokinetics, and optimizing your treatment journey.
GLP-1 Medication Hubs
Comprehensive guides for each GLP-1 medication—dosing protocols, clinical trial data, microdosing strategies, and our free calculators.
Semaglutide Guide
Ozempic & Wegovy: GLP-1 receptor agonist. ~15% weight loss, 7-day half-life. FDA-approved for diabetes and weight management.
Tirzepatide Guide
Mounjaro & Zepbound: Dual GLP-1/GIP agonist. ~21% weight loss, 5-day half-life. The first dual-agonist approved by FDA.
Retatrutide Guide
Triple GLP-1/GIP/Glucagon agonist. ~24% weight loss in trials, 6-day half-life. Expected FDA approval 2027.
Educational Content
Tirzepatide Dosage Chart 2026: Mounjaro & Zepbound Titration
guidesComplete tirzepatide dosage chart showing Mounjaro and Zepbound titration protocols week-by-week from 2.5mg to 15mg. Includes what to expect at each dose level, side effects by tier, printable download, and a free dosing calculator.
Mounjaro vs Zepbound: Same Drug, Different Names (2026)
comparisonMounjaro and Zepbound contain identical tirzepatide (LY3298176). The differences are indication, device, and insurance: not the molecule. Full comparison with cost data and decision framework.
Tirzepatide Calculator & Guide: Mounjaro & Zepbound Dosing (2026)
hubFree tirzepatide dosing calculator plus complete guide. Visualize Mounjaro/Zepbound drug levels, plan titration schedules, understand half-life pharmacokinetics, and manage side effects.
Semaglutide Side Effects: Ozempic, Wegovy & Rybelsus Complete Guide (2026)
guideSemaglutide side effects guide: nausea, diarrhea, and GI symptoms from STEP and SUSTAIN trials, plus practical management tips.
Tirzepatide Side Effects: What to Expect & How to Manage (2026 Guide)
guideTirzepatide side effects guide: nausea, diarrhea, and other GI symptoms from clinical trial data, plus practical management tips.
Semaglutide Guide: Ozempic & Wegovy Complete Resource
hubEverything you need to know about semaglutide (Ozempic/Wegovy): GLP-1 mechanism, FDA-approved dosing protocols, half-life pharmacokinetics, side effects, and our free calculator to track your journey.
What Is Tirzepatide? GIP + GLP-1 Dual-Agonist Explained
articleTirzepatide is a dual GIP/GLP-1 receptor agonist approved as Mounjaro (type 2 diabetes) and Zepbound (weight loss, sleep apnea). Clinical trials show up to 20.9% weight loss. This guide explains the science clearly.
Ozempic vs Wegovy 2026: Cost, Dosing, Weight Loss Compared
comparisonBoth Ozempic and Wegovy contain semaglutide, but Ozempic is FDA-approved for type 2 diabetes (max 1.0 mg) while Wegovy targets obesity (2.4 mg recommended maintenance, 7.2 mg maximum). Explore the differences.
Semaglutide Dosage Chart: Ozempic vs Wegovy Titration Schedule (2026)
guidesComplete semaglutide dosage chart showing Ozempic (2.0 mg max) and Wegovy (2.4 mg maintenance, 7.2 mg max) titration protocols week-by-week. Includes what to expect at each dose level, side effects data, printable download, and a free dosing calculator.